News

Genascence Announces Initiation of Phase 1b Clinical Trial of GNSC-001 Gene Therapy for Knee Osteoarthritis (OA)

January 3, 2024 Press Release

Genascence to Present at Biotech Showcase 2024

December 20, 2023 Press Release

Genascence to Present Full Data from Phase 1 Clinical Trial on GNSC-001, Company’s Lead Program in Osteoarthritis, at European Society of Gene & Cell Therapy 30 th Annual Congress

October 24, 2023 Press Release

Genascence Names Ian Lachlan McLean, M.D. Ph.D. as Chief Medical Officer

October 18, 2023 Press Release

Genascence Receives $11.6 Million Award From California Institute for Regenerative Medicine to Help Advance its Lead Gene Therapy Program in Knee Osteoarthritis

February 23, 2023 Press Release

Genascence Announces Data From Phase 1 Clinical Trial on GNSC-001, Company’s Lead Program in Osteoarthritis, Presented at American Society of Gene & Cell Therapy 25th Annual Meeting

May 17, 2022 Press Release

Genascence Announces First Close in Series A Financing led by Pacira BioSciences and Expands Board of Directors and Scientific Advisory Board

May 10, 2022 Press Release

Genascence Announces Completion of Dosing and Interim Safety Data for Phase 1 Clinical Trial of GNSC-001 in Osteoarthritis

May 5, 2022 Press Release